DOV-216,303

DOV-216,303
Legal status

Legal status	US: Investigational New Drug
Identifiers
IUPAC name 1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane
CAS Number	410074-75-8^N
PubChem CID	9795276
ChemSpider	7971043^N
ChEMBL	CHEMBL528995^N
Chemical and physical data
Formula	C₁₁H₁₁Cl₂N
Molar mass	228.117 g/mol
3D model (Jmol)	Interactive image
SMILES C1C2C1(CNC2)C3=CC(=C(C=C3)Cl)Cl
InChI InChI=1S/C11H11Cl2N/c12-9-2-1-7(3-10(9)13)11-4-8(11)5-14-6-11/h1-3,8,14H,4-6H2^N Key:BSMNRYCSBFHEMQ-UHFFFAOYSA-N^N
^NY (what is this?)

DOV 216,303 is an antidepressant drug originally developed by DOV Pharmaceutical and was licensed to Merck & Co. in 2004; Merck and Dov terminated their relationship in December 2006.

It is a triple reuptake inhibitor (TRI), or serotonin-norepinephrine-dopamine reuptake inhibitor (SNDRI). It is the racemic mixture of amitifadine (DOV-21,947) and its (–)-enantiomer, DOV-102,677. Its IC₅₀ values for SERT, NET, and DAT are K_i 14 nM, 20 nM, and 78 nM, respectively.

As of March 2008, Dov had no intention to further develop DOV-216,303 because the patent on the compound had expired.